chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I was monitored for 15 minutes after my vaccination and was fine. During my 30 min drive home I slowly developed symptoms, first sneezing/ stuffiness, then coughing, then hives, and wheezing and difficulty breathing. I took an epi-pen which helped with the breathing. My hives returned about an hour after my epi-pen dose.
Developed temp of 104.5 at about twenty-four hours after vaccination and had febrile seizure (first episode). had second short seizure. Seen in emergency dept at North Hawaii Community Hospital. No focus of infection. Observed and sent home.
PT SAID SHE HAD A BIT OF SORENESS AT SITE. SHE APPROXIMATELY 2 DAYS LATER GOT THE SHINGLES. WENT TO URGENT CARE TODAY AND WAS GIVEN VALTREX AND PREDNISONE
Patient was ordered to received Meningococcal MCV4 rather than Meningococcal B.  No adverse event experienced by patient but incorrect vaccine administered versus what was ordered.
ADVERSE EVENT NOS; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the subject experienced adverse event nos. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of adverse event nos was not reported. This report was non-serious. This case, from the same reporter is linked to 20210425196.
patient was not due for Hep B, was given Hep B in error, No adverse reaction reported by mom
Extreme chills with shivering, fever of 101°, starting approximately 11 hours post vaccination, treated with Ibuprofen and lasting approximately 12 hours. Intense muscular and joint pain began approx. 17 hours post vaccination and lasted approx. 15 hours before tapering off. Treated with Ibuprofen and went away after about 2 days.
cramps on her upper thigh/leg cramps; hard time to sleep; This spontaneous case was reported by a consumer and describes the occurrence of MUSCLE SPASMS (cramps on her upper thigh/leg cramps) and INSOMNIA (hard time to sleep) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 060h21b) for COVID-19 vaccination.     The patient's past medical history included Leg cramps.    On 11-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In December 2021, the patient experienced MUSCLE SPASMS (cramps on her upper thigh/leg cramps) and INSOMNIA (hard time to sleep). At the time of the report, MUSCLE SPASMS (cramps on her upper thigh/leg cramps) and INSOMNIA (hard time to sleep) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient mentioned that she listened to somebody else saying "they experienced something worst".  Concomitant medications was not reported.  The patient did not receive any treatment medications at the time of this report.   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2021: Non significant follow up appended
The day after I received my fourth dose of Pfizer, I began to experience some aches and pain in my left foot and I also had a slight fever of 99 degrees. The next day my foot began to swell and the symptoms were similar to what I experience with Rheumatoid arthritis and I was unable to walk. Since then my left knee has also began to swell. The pain has subsided some, around 20-30% but the swelling has remained the same and my fever went away around 2-3 days after I first noticed it.
Moderate joint pain in all joints since vaccine; This is a spontaneous report from a contactable consumer [Patient (reported for himself)]. A 86-year-old elderly male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Product: COVID 19, brand: Pfizer, Lot number: EL9264, Lot unknown: False), dose 1 via an unspecified route of administration, administered in Left arm on 20Feb2021 10:00 am (at the age of 86-year-old) as Dose 1, Single for covid-19 immunisation. Medical history included type 2 diabetes and prostate cancer. If covid tested post vaccination: No. There were no Known allergies. Patient did not receive any other vaccines within four weeks. The patient's concomitant medications were not reported. The patient experienced moderate joint pain in all joints since vaccine (non-serious) on 21Feb2021 10:00 am. Adverse event: Moderate joint pain in all joints since vaccine. It has been 2 weeks since 1st injection and joint pain still exists. Ae resulted in: None. Facility where the most recent COVID-19 vaccine was administered was Hospital. Prior to vaccination, patient was not diagnosed with COVID-19. The outcome of event was not recovered.    No follow-up attempts are possible. No further information is expected.
Dizziness left arm pain, chills, fatigue, shortness of breath, continues shortness of breath and fatigue as of 2/19/21 patient continues to have shortness of breath and fatigue, to follow up with primary care physician
it was rpt fr HCP concerning pt who in approx 1995 was vax & in 1999 pt exp a lack of seroconversion. addl info requested
Right sided migraine started 6 hours after vaccine. Started at back of head and radiated up to too of head near forehead hairline. Then right side of face went numb for 30 minutes, forehead, cheek, chin, ear. I did neuro exam on myself, funny faces sticking tongue out and overhead arm raises, all normal. It was terrifying and concerned for a stroke despite being 36yo. Felt dizzy and could not turn my head bc room would spin. Worst headache of my life and first time ever having facial numbness. The numbness passed but severe dizzy could not move head for nearly 2 hours. Dizzy decreased and brushed teeth early and went to bed. Slept 12 hours, woke up and nearly crawled to bathroom and back bc dizzy, mild brief nausea, and residual headache. Slept for another 4 hours and woke up tired but no longer nauseated dizzy or headache. Felt tired until the next morning, then ok.
pt recv vax 24SEP96 & 25SEP96 lt deltoid area was swollen, firm & warm to touch;by 27SEP area had dec in size & firmness but still warm to touch;30SEP lt deltoid area looks much better no swelling or firmness noted;
Pt reported a red rash going down her arm. Pt denied any pain, itching, or other discomfort. Advised pt that rash is a normal reaction to this vaccine and to continue to self monitor for any changes
Patient called  and talked to staff in the clinic(date of this phone call is unknown) Staff brought this note to nurse in county health and this nurse called and talked to pt mother about adverse reaction. Mother stated that 1-2-2020 in the pm she noticed that on pt left thigh he had a hard nodule and a bright red area that was hot to the touch to the left thigh where mmr immunization was given. This nurse called and talked to pt mother today and said "redness and hot to the touch area of left leg was gone."  Mother also did not take pt to a doctors office or medical professional for evaluation of this.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site itching in a 18-year-old female patient who received MENVEO (batch number M17032, expiry date March 2019). On 28th April 2018, the patient received the 1st dose of MENVEO. On an unknown date, less than a week after receiving MENVEO, the patient experienced injection site itching, injection site rash and headache. On an unknown date, the outcome of the injection site itching, injection site rash and headache were recovering/resolving. It was unknown if the reporter considered the injection site itching, injection site rash and headache to be related to MENVEO. The reporter is a pharmacist reporting this case on behalf of the patient. In 2018, the reporter stated that, last night she noticed that there was a circle at the injection site with itchiness and rash. The patient also reported that, the patient experienced headache that started last night as well.
Info has been received from a pharmacist concerning a pt who on 4/23/04 was vaccinated with a dose of hepatitis A virus vaccine inactivated. Suspect concomitant therapy included a 2nd dose of hepatitis B virus vaccine. On approximately 4/23/04, 'sometime between vaccination and the morning of 4/26/04', the pt developed hives, a generalized rash and facial swelling. There was no treatment required. Unspecified medical attention was sought. There was no product quality complaint involved. Additional info has been requested.
Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Mild, Systemic: Dizziness / Lightheadness-Mild
This spontaneous report as received from a health care professional refers to a 49 year old female patient. On 02-NOV-2011, the patient was vaccinated with a first dose of ZOSTAVAX (lot # 671611/1161AA, expiration date 18-OCT-2012) intramuscularly instead of subcutaneously. Additional information has been requested.
About 1 week after receiving the first shot, I noticed my hair started to fall out. I went to the dermatologist who said I had telogen effluvium (temporary hair loss). They said it occurs when something "shocks" the bodies system. I have also seen an endocrinologist to rule out all illnesses/diseases (all tests came back negative). I have seen so many doctors and everyone tells me something different. I saw another dermatologist who said the hair loss can last from 6 months to 2 years. I am now suffering from anxiety and stress because of this and nothing seems to be working. My scalp is sore all the time and sometimes burns. It is extremely uncomfortable. The dermatologist can't see anything (meaning it is some underlying symptom).
This spontaneous report was received from a physician referring to an unknown number of patients of unknown gender and age. Pertinent medical history or concurrent conditions were not reported. Since 30-MAY-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB which had the lot # reported as N00236, expiration date 24-OCT-2019, lot # N000235, expiration date 26-OCT-2019, lot # N003536, expiration date 02-NOV-2019, for prophylaxis (dosage information and route were not informed). Information regarding concomitant medication was not provided. Additionally, it was reported that the lowest temperature was 32 degrees Fahrenheit and the highest was 54 degrees Fahrenheit for 49 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. This is one case from several cases from the same reporter. Follow-up information has been received from a physician on 16-OCT-2017 to an unknown number of patients of unknown gender and age. The patients' concomitant medications, pertinent medical history, drug reactions or allergies were not reported. Since 29-APR-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB (lot # M046140, expiration date 27-SEP-2019, dosage information and route were not provided) for prophylaxis. Additionally, it was reported that the lowest temperature was 47° degrees Fahrenheit and the highest was 49° degrees Fahrenheit for 16 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. Follow up information was received from the physician on 27-OCT-2017. This report refers to 4 month old patient. On 10-JUN-2017, the patient was vaccinated with improperly stored doses of PEDVAXHIB lot# N000235 with expiration date: 26-OCT-2019. This is one case from several cases from the same reporter. Sender's Comments: US-009507513-1709USA012770: US-009507513-1709USA012767: US-009507513-1709USA012768: US-009507513-1709USA012769: US-009507513-1709USA012765: US-009507513-1709USA012764: US-009507513-1709USA007325: US-009507513-1709USA012766.
pt devel hives & wheals following vax w/MMR; pt was treated w/DPH; No further details were provided;
This spontaneous report as received from a pharmacist refers to a male patient of unknown age. Concurrent conditions and medical history were not reported. On 18-SEP-2015, the patient was vaccinated with a dose of ZOSTAVAX. Concomitant medication was not reported. Approximately on an unknown date in September 2015, within 2 to 3 days after vaccination, the patient was diagnosed with herpes zoster on one side of the face surrounding the eye with black blisters in the center of the rash (herpes zoster). Patient sought medical attention for the same (saw a physician). The outcome of herpes zoster was unknown. The causality was not reported. Additional information has been requested.
I woke up Saturday at 7 AM felt a little achy laid back down and by 10 AM was unable to get out of bed I had severe aches and pains on a scale of 1 to 10 was a 9, unable to sit up or stand. Very bad fatigue.  A very bad throbbing headache from Saturday until Monday that Tylenol would not help.
10/4/2022 I had a terrible headache that took three days to go away. I had acupunctured the day before. I had diarrhea, vomiting and I was severely fatigued. It took 72 to 96 hours to go get better. I had very little appetite for 10 days. I had multiple Covid tests that were negative (no dates).
Frozen ice pack was placed inside a cooler adjacent to a syringe containing Pfizer COVID-19 vaccine. Nurse was unable to administer the vaccine as the solution inside the syringe had frozen. The ice pack was removed, the syringe was wasted, and the patient was vaccinated with a separate syringe. Other syringes in the cooler were not affected in this manner upon visual inspection.
EXPIRED VACCINE ADMINISTRATION; This spontaneous report received from a health care professional concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A expiry: 21-SEP-2021) dose was not reported, administered on 24-SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On 24-SEP-2021, the patient experienced expired vaccine administration. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired vaccine administration was not reported. This report was non-serious.
Pt recvd flu vax & devel low grade fever, malaise, runny nose & cough;
This is a spontaneous report from a contactable pharmacist. A female patient of an unspecified age received PREVNAR 13, via an unspecified route of administration from an unspecified date at single dose for immunisation. The patient's medical history and concomitant medications were not reported. Caller wanted to know if neck pain was related to the administration of a second dose of PREVNAR 13 after a year of the first dose. Caller stated that patient was not sure she received a previous dose of PREVNAR 13, Patients was not sure when she received the dose and where. Outcome of the event was unknown.
This spontaneous report as received from a pharmacy technician refers to a 62 years old female patient with no pertinent medical history and no drug reaction/allergies. The patient was vaccinated with ZOSTAVAX (Lot#Exp, dose/frequency, dose number and therapy route were unspecified) in November-2011. No other co-suspects were reported. No concomitant medications were taken. It was reported that on 16-JUL-2012 the patient was diagnosed with shingles. The patient had sought medical attention via office visit. No lab diagnostics studies performed. No treatment information was reported. The outcome was unknown when reporting. Additional information has been requested.
No adverse event; The patient was administered with improperly stored VAQTA; This spontaneous report was received from a certified medical assistant (CMA) referring to a 18-month-old male patient.  No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant medications was provided.  On 08-NOV-2019, the patient was vaccinated with improperly stored hepatitis a vaccine, inactivated (VAQTA) (lot # S007770, expiration date: 24-JUL-2020, strength, dose number, anatomical location and route of administration were not reported) for prophylaxis (product storage error). It was reported that the vaccine was exposed to the temperature above 47 degrees Fahrenheit/9 degree Celsius (9.3 Celsius) for 23 minutes. The previous temperature excursion were at the temperature above 47 degrees Fahrenheit/9 degree Celsius (10.7 Celsius) for 33 minutes, at the temperature above 47 degrees Fahrenheit/9 degree Celsius (8.7 Celsius) for 36 minutes, at the temperature above 47 degrees Fahrenheit/9 degree Celsius (8.9 Celsius) for 15 minutes and at the temperature above 47 degrees Fahrenheit/9 degree Celsius (9 Celsius) for 12 minutes. The call was because of a data logger. No adverse event was reported.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S007770; expirationdate: 24-JUL-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-1910USA012749:
no adverse event; expired on February 12,2023 which the vaccine was administered on February 16th; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired on February 12,2023 which the vaccine was administered on February 16th) and NO ADVERSE EVENT (no adverse event) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 16-Feb-2023, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Feb-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (expired on February 12,2023 which the vaccine was administered on February 16th). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (expired on February 12,2023 which the vaccine was administered on February 16th) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (expired on February 12,2023 which the vaccine was administered on February 16th).    No concomitant medication information was reported. It was reported that she just noticed today that her vaccine was expired on EMR which it expired on February 12,2023 which the vaccine was administered on February 16th but the vial and the box did not have an expiration date on it. No treatment medication information was reported.
Left hand, arm, face, lip were tingly. Slightly dizzy when symptoms began. Tingly feeling has lasted almost 24 hours to varying degrees but has not fully gone away yet.
I feel burn on my esophagus.; pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 19Mar2021 (Lot number: EN6207) at the age of 34 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Gastric issues" (unspecified if ongoing), notes: Gastric issues. Concomitant medication(s) included: AMITRIPTYLINE; VITAMIN D; PANTOPRAZOLE; PHAZYME. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE , Lot number: EL6203 Anatomical site- Arm Right Age at vaccination:34 years, Severe Gastric Issues - I had the issue for a year in a mild format. After first dose I got really bad but I tried to manage that and I thought that is related to the old issue), administration date: 26Feb2021, when the patient was 34 years old, for COVID-19 immunisation, reaction(s): "Gastric disorder". The following information was reported: BURN OESOPHAGEAL (non-serious) with onset 20Mar2021 03:00, outcome "not recovered", described as "I feel burn on my esophagus."; PAIN (non-serious) with onset 20Mar2021 03:00, outcome "not recovered", described as "pain". Therapeutic measures were not taken as a result of burn oesophageal, pain.  Additional Information: A 34-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207), via an unspecified route of administration in the right arm on 19Mar2021 (at the age of 34-years-old), as a single dose for COVID-19 immunisation. Medical history included gastric issues for 1 year in a mild format. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included pantoprazole (MANUFACTURER UNKNOWN), amitriptyline (MANUFACTURER UNKNOWN), simethicone and calcium carbonate (PHAZYME), and vitamin D (MANUFACTURER UNKNOWN) for unknown indication. The patient had previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL6203), via an unspecified route of administration in the right arm on 26Feb2021 at 19:00 (at the age of 34-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 20Mar2021 at 03:00, it was reported that the patient had severe gastric issues for a year in a mild format. After the first dose the patient had experienced really bad and tried to manage. On 19Mar2021, the patient got the second dose and she was having pain and had felt burn in her oesophagus on 20Mar2021 at 03:00. The patient did not receive any treatment for the adverse events. The clinical outcome of the events pain and burn in oesophagus were not resolved.  No follow-up attempts are possible. No further information is expected.
No additional AEs; administered an expired dose of GARDASIL 9; This spontaneous report was received from the patient's mother concerning a 12-year-old male patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On an unspecified day in June 2022, the patient was vaccinated with a possibly expired dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) for prophylaxis (dose, injection anatomical location, route of administration lot # and expiration date were not provided) (Expired product administered). The reported stated that the dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) administered was expired by 3 months, and when she questioned the healthcare professional (HCP) about it, the HCP provided a different lot number that was no expired. The reporter was concerned about the HCP not being truthful about which lot was administered. No adverse events were reported (No adverse event).